convalescent plasma treatment - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 2.75 [0.50, 15.09]< 10%2 studies (2/-)12.3 %some concernnot evaluable moderatecrucial-
deaths 1.28 [0.20, 8.11]< 133%3 studies (3/-)39.8 %lownot evaluable highcrucial-
hospitalization or death 0.91 [0.63, 1.33]< 10%1 study (1/-)68.1 %NAnot evaluable crucial-
hospitalization 0.95 [0.75, 1.20]< 10%3 studies (3/-)67.2 %lownot evaluable highimportant-
mechanical ventilation 1.49 [0.25, 9.02]< 10%1 study (1/-)33.2 %NAnot evaluable important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.